Sinopharm Group CoSHTDF -2.67%78 PE Ratio without NRI is 6.12 as of Jun. 24, 2026, which is 5% below its 10-year median of 6.45. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $3.03 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 89 Medical Distribution companies, Sinopharm Group Co ranks better than 96.63% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-24), Sinopharm Group Co's share price is $2.2872.
Sinopharm Group Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $0.37. Therefore, Sinopharm Group Co's PE Ratio without NRI for today is 6.12.
During the past 13 years, Sinopharm Group Co's highest PE Ratio without NRI was 25.98. The lowest was 4.07. And the median was 6.45.
Sinopharm Group Co's EPS (Basic) for the
six
months ended in Dec. 2025 was $0.17.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.32.
Sinopharm Group Co (OTCPK:SHTDF) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Sinopharm Group Co PE Ratio without NRI Related Terms
Sinopharm Group Co PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHTDF vs MCK, COR, CAH: PE Ratio without NRI Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co PE Ratio without NRI vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's PE Ratio without NRI falls into.
Sinopharm Group Co PE Ratio without NRI Calculation
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Sinopharm Group Co's Share Price of today is $2.2872.
For company reported semi-annually, Sinopharm Group Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.37.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Sinopharm Group Co (SHTDF) has a PE Ratio without NRI of 6.12 as of Jun. 24, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Sinopharm Group Co and its competitors. This is near median its historical median of 6.45. Over the past decade, Sinopharm Group Co's PE Ratio without NRI has ranged from 4.07 to 25.98. According to the industry distribution chart, Sinopharm Group Co ranks #3 out of 89 companies in the Medical Distribution industry, placing it in the top 3.4%.
Is Sinopharm Group Co's PE Ratio without NRI too high?
Sinopharm Group Co's current PE Ratio without NRI of 6.12 is near median its 10-year median of 6.45. Over the past 10 years, this metric has ranged from a low of 4.07 to a high of 25.98. The Medical Distribution industry median PE Ratio without NRI is 15.20. Sinopharm Group Co's value of 6.12 is 59.7% below this industry median. Based on the distribution chart, Sinopharm Group Co ranks #3 out of 89 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's PE Ratio without NRI compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #3 out of 89 companies for PE Ratio without NRI. This places Sinopharm Group Co in the top 3% of its industry — outperforming the majority of peers. The industry median PE Ratio without NRI is 15.20. Sinopharm Group Co's value of 6.12 is 59.7% below this benchmark. Historically, Sinopharm Group Co's own PE Ratio without NRI has ranged from 4.07 to 25.98 over the past decade. While the company's 10-year median is 6.45 vs. the industry median of 15.20, Sinopharm Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Distribution company?
The median PE Ratio without NRI among Medical Distribution companies is 15.20, based on 89 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current PE Ratio without NRI of 6.12 is 59.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median PE Ratio without NRI is 15.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current PE Ratio without NRI is 6.12, which is near median its own 10-year median of 6.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.03, compared to a current price of $2.29 — trading 24.5% below its estimated fair value. The current PE Ratio without NRI is 6.12, which is near median its 10-year median of 6.45 and 59.7% below the Medical Distribution industry median of 15.20. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current PE Ratio without NRI is 6.12 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.29 is trading 24.5% below its estimated GF Value™ of $3.03.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
PE Ratio without NRI: 6.12 (near median its 10-year median of 6.45)
GF Value™: $3.03 vs. price of $2.29 (24.5% below fair value)
Industry Position: 59.7% below the Medical Distribution median (#3 of 89)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
